Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and best dose of venetoclax and romidepsin to
see how well it works in treating patients with mature T-cell lymphoma that has come back
(recurrent) or does not respond to treatment (refractory). Venetoclax and romidepsin may stop
the growth of cancer cells by blocking some of the enzymes needed for cell growth.